OTCMKTS:CHGCY Chugai Pharmaceutical Q3 2026 Earnings Results & Report $21.47 -0.32 (-1.47%) As of 03:06 PM Eastern Chugai Pharmaceutical reported Q3 2026 earnings on October 27, 2026. The company reported EPS of $0.27. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market Opens Chugai Pharmaceutical EPS ResultsActual EPS$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AChugai Pharmaceutical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Chugai Pharmaceutical Q3 2026 Earnings FAQ Did Chugai Pharmaceutical beat earnings estimates for Q3 2026? Chugai Pharmaceutical (OTCMKTS:CHGCY) reported earnings of $0.27 per share for Q3 2026. The report was announced on Tuesday, October 27, 2026. Chugai Pharmaceutical Earnings HeadlinesChugai Pharmaceutical (OTCMKTS:CHGCY) versus IM Cannabis (NASDAQ:IMCC) Head to Head ComparisonOctober 26 at 4:29 AM | americanbankingnews.comChugai Pharmaceutical Co. - Depositary receipt price target decreased by 15.22% to $26.89October 23, 2026 | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)CHGCY - Chugai Pharmaceutical Co., Ltd.October 12, 2026 | seekingalpha.comChugai Pharmaceutical Co. Ltd. ADRAugust 19, 2026 | wsj.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comSee More Chugai Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email. Email Address About Chugai PharmaceuticalChugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies. The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder. Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche. Chugai remains an independent company, with Roche serving as a major global development and commercialization partner for a number of its medicines.View Chugai Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
